Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Evommune logo — Developing innovative therapies that target key drivers of c...

Evommune

Developing innovative therapies that target key drivers of chronic inflammatory diseases.

Founded 2020 United States Palo Alto, United States 69 employees Total: $493.00M Biotechnology, Health Care +1

General Information

Company Name Evommune
Founded Year 2020
Location United States Palo Alto, United States
Founders / Decision Makers
Team member
Employees 69
Industries Biotechnology, Health Care, Life Sciences
Business Model B2B, B2D
Revenue Model Licensing, Performance Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Evommune. To contact Evommune, visit evommune.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Evommune compare?

A PDF of Evommune and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Evommune soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Evommune

Evommune, founded in 2020, is a pioneering company in the fields of Biotechnology, Health Care, and Life Sciences, based in the United States. The company is making strides in addressing the pervasive challenge of chronic inflammation, which affects millions globally and is a precursor to numerous serious health conditions.

Driven by its slogan, "Developing innovative therapies that target key drivers of chronic inflammatory diseases," Evommune is committed to advancing medical treatments that significantly enhance patients' quality of life by preventing the severe consequences of existing therapeutic limitations.

The company recently secured a substantial $7.50M in a Series B funding round on 28 June 2023, backed by Verition Fund Management. This investment underscores the confidence in Evommune's mission and its potential to deliver breakthroughs in inflammation management therapies.

Business keywords: Chronic Inflammatory Diseases, Innovative Therapies, Tissue-Based Approach, Transformative Medicines, Disease Progression Prevention, Inflammatory Disorders, Best-in-Class Profiles, Patient Care, Research and Development, Symptom Management, Healthcare Innovation, Therapeutic Development, Pipeline Development

Services & Products

Discovery and development of therapies for chronic inflammatory diseases
Pipeline advancement of product candidates
Hosting webinars and sharing scientific insights

Target Customers

Patients with chronic inflammatory diseases Healthcare professionals

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Private Placement Non VC $125.00M -
01 Feb 2026
IPO $150.00M -
01 Nov 2025
Series C $115.00M 18
Longwood Fund RA Capital Management Pivotal bioVenture Partners
Longwood Fund, RA Capital Management +16
01 Oct 2024
Series B $7.50M 1
Verition Fund Management
Verition Fund Management
01 Jun 2023
Series A $83.00M 3
Andera Partner
Andera Partner, EQT Life Sciences +1
01 Sep 2021
Seed $12.50M 1
Pivotal Life Sciences
01 Nov 2020

Evommune Alternatives & Competitors

View All Alternatives
Evommune vs
FimmCyte
FimmCyte Switzerland

First disease modifying treatment for Endometriosis.

Seed
7 employees
Biotechnology, Health Care
Compare Evommune vs FimmCyte
Evommune vs
CV6 Therapeutics, (NI) Ltd.
CV6 Therapeutics, (NI) Ltd. United Kingdom

CV6 Therapeutics is dedicated to improving patients lives through the development of novel and innov...

Venture round
11 employees
Biotechnology, Health Care
Compare Evommune vs CV6 Therapeutics, (NI) Ltd.
Evommune vs
Ultragenyx
Ultragenyx United States

Going Beyond Every Day

Post-IPO Equity
1535 employees
Biotechnology, Health Care
View all alternatives

FAQ About Evommune

Developing innovative therapies that target key drivers of chronic inflammatory diseases.
Evommune was founded in 2020.
Evommune is headquartered in Palo Alto, United States.
Evommune operates in Biotechnology, Health Care and Life Sciences. Its work centres on Chronic Inflammatory Diseases, Innovative Therapies, Tissue-Based Approach and Transformative Medicines. Its customers include Patients with chronic inflammatory diseases and Healthcare professionals.
Evommune has a B2B and B2D business model. Its revenue comes from Licensing, Performance Based and Product Sales.
Evommune has approximately 69 employees.
Evommune has completed 6 funding rounds, raising a total of $493.00M.
Evommune offers: Discovery and development of therapies for chronic inflammatory diseases, Pipeline advancement of product candidates, Hosting webinars and sharing scientific insights.
Top alternatives and competitors to Evommune include FimmCyte, CV6 Therapeutics, (NI) Ltd., Ultragenyx, BIORCHESTRA Co., Ltd., ACELYRIN, INC.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Evommune and FimmCyte are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Evommune, https://bouncewatch.com/company/evommune, updated 4 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes